共 106 条
[1]
Thomas MC(2015)Diabetic kidney disease Nat Rev Dis Primers. 171 1920-1927
[2]
Brownlee M(2011)Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study Arch Intern Med 380 807-814
[3]
Sustak K(2012)Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study Lancet 18 2766-2772
[4]
Shurraw S(2007)Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study J Am Soc Nephrol 2 1131-1139
[5]
Hemmelgarn B(2007)Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study Clin J Am Soc Nephrol. 26 1888-1894
[6]
Lin M(2011)Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study Nephrol Dial Transpl 64 317-327
[7]
Tonelli M(2007)Effect of renal impairment on the pharmacokinetics of exenatide Br J Clin Pharmacol 10 1568-1574
[8]
Muntner P(2015)Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy Clin J Am Soc Nephrol. 85 962-971
[9]
Lloyd A(2014)Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Kidney Int 9 529-550
[10]
Perkovic V(2013)Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease Expert Opin Drug Metab Toxicol. 42 207-210